LXI 15029

Next Previous
Drug Profile

LXI 15029

Alternative Names: LXI15029; SCC-31

Latest Information Update: 27 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chinese Academy of Sciences; Fudan University; Shandong Luoxin Pharmaceutical; Shanghai Institute of Materia Medica
  • Developer Chinese Academy of Sciences; Shandong Luoxin Pharmaceutical; Shanghai Institute of Materia Medica
  • Class Antineoplastics
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 12 Jun 2017 Phase-I clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (PO) (NCT03125746)
  • 12 Jun 2017 Phase-I clinical trials in Breast cancer (Monotherapy, Late-stage disease, Metastatic disease) in China (PO) (NCT03125746)
  • 04 May 2017 Shandong Luoxin Pharmaceutical plans a phase I trial for Breast cancer (Late-stage disease, Monotherapy, Combination therapy, Metastatic disease) (NCT03125746)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top